清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial

医学 托法替尼 类风湿性关节炎 打开标签 恶性肿瘤 内科学 皮肤病科 随机对照试验 肿瘤坏死因子抑制剂 临床试验 关节炎 肿瘤科 阿达木单抗
作者
Jeffrey R. Curtis,Kunihiro Yamaoka,Yi‐Hsing Chen,Deepak L. Bhatt,Levent M Gunay,Naonobu Sugiyama,Carol A. Connell,Cunshan Wang,Joseph Wu,Sujatha Menon,Ivana Vranić,Juan J. Gómez‐Reino
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:82 (3): 331-343 被引量:101
标识
DOI:10.1136/ard-2022-222543
摘要

To evaluate malignancies and their associations with baseline risk factors and cardiovascular risk scores with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA).In an open-label, randomised controlled trial (ORAL Surveillance; NCT02092467), 4362 patients with RA aged ≥50 years with ≥1 additional cardiovascular risk factor received tofacitinib 5 (N=1455) or 10 mg two times per day (N=1456) or TNFi (N=1451). Incidence rates (IRs; patients with first events/100 patient-years) and HRs were calculated for adjudicated malignancies excluding non-melanoma skin cancer (NMSC), NMSC and subtypes. Post hoc analyses for malignancies excluding NMSC, lung cancer and NMSC included risk factors identified via simple/multivariable Cox models and IRs/HRs categorised by baseline risk factors, history of atherosclerotic cardiovascular disease (HxASCVD) and cardiovascular risk scores.IRs for malignancies excluding NMSC and NMSC were higher with tofacitinib (combined and individual doses) versus TNFi. Risk of lung cancer (most common subtype with tofacitinib) was higher with tofacitinib 10 mg two times per day versus TNFi. In the overall study population, the risk of malignancies excluding NMSC was similar between both tofacitinib doses and TNFi until month 18 and diverged from month 18 onwards (HR (95% CIs) for combined tofacitinib doses: 0.93 (0.53 to 1.62) from baseline to month 18 vs 1.93 (1.22 to 3.06) from month 18 onwards, interaction p=0.0469). Cox analyses identified baseline risk factors across treatment groups for malignancies excluding NMSC, lung cancer and NMSC; interaction analyses generally did not show statistical evidence of interaction between treatment groups and risk factors. HxASCVD or increasing cardiovascular risk scores were associated with higher malignancy IRs across treatments.Risk of malignancies was increased with tofacitinib versus TNFi, and incidence was highest in patients with HxASCVD or increasing cardiovascular risk. This may be due to shared risk factors for cardiovascular risk and cancer.NCT02092467, NCT01262118, NCT01484561, NCT00147498, NCT00413660, NCT00550446, NCT00603512, NCT00687193, NCT01164579, NCT00976599, NCT01059864, NCT01359150, NCT02147587, NCT00960440, NCT00847613, NCT00814307, NCT00856544, NCT00853385, NCT01039688, NCT02281552, NCT02187055, NCT02831855, NCT00413699, NCT00661661.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
8秒前
11秒前
null的应助被科研通管家采纳,获得10
11秒前
CipherSage的应助被TingtingGZ采纳,获得10
21秒前
zy997987876完成签到,获得积分10
24秒前
温婉的连虎完成签到,获得积分10
28秒前
29秒前
TingtingGZ发布了新的文献求助10
34秒前
34秒前
34秒前
李红莲完成签到,获得积分10
37秒前
39秒前
舒心谷菱完成签到,获得积分10
47秒前
Raju发布了新的文献求助10
49秒前
57秒前
vitamin完成签到 ,获得积分0
1分钟前
1分钟前
喜悦的乐驹完成签到,获得积分10
1分钟前
漂亮秋荷完成签到,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
2分钟前
TingtingGZ完成签到,获得积分10
2分钟前
TingtingGZ发布了新的文献求助10
2分钟前
优美的烙完成签到,获得积分10
2分钟前
2分钟前
活力的尔蓉完成签到,获得积分10
2分钟前
2分钟前
2分钟前
A29964095完成签到 ,获得积分10
2分钟前
2分钟前
喷火球发布了新的文献求助100
2分钟前
开心的寄柔完成签到,获得积分10
2分钟前
blenx完成签到,获得积分10
3分钟前
3分钟前
迷路万天完成签到,获得积分10
3分钟前
3分钟前
3分钟前
隐形忆丹完成签到,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173161
求助须知:如何正确求助?哪些是违规求助? 9565558
关于积分的说明 21780458
捐赠科研通 7767231
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555697
邀请新用户注册赠送积分活动 2476682